Innoplexus
Innoplexus (Partex.AI) is a Germany-based AI-native drug discovery platform combining AlphaFold2, MolMIM, and DiffDock on NVIDIA H100 infrastructure to accelerate virtual screening and incubate therapeutic assets for pharmaceutical and biotech partners.
- Company typePrivate
- Founded2011
- HeadquartersEschborn, Germany
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Innoplexus does
Innoplexus, now operating as Partex.AI (legal entity Partex NV), is a Germany-headquartered AI-powered therapeutic asset accelerator founded in 2011 with 251-500 employees. The company operates four integrated business units: Therapeutics (identifying and optimizing late preclinical to early clinical drug assets, currently incubating three oncology assets in dedicated SPVs), Exchange (AI-driven in- and out-licensing platform for deprioritized or off-strategy drug assets), Labs (wet-lab functional assays and high-throughput experimental validation creating a closed-loop with computational predictions), and Real-World Data (global healthcare-provider partnerships for evidence generation). Its underlying platform combines AlphaFold2 for protein structure prediction (with stated focus on TDP-43 aggregation targets in neurodegenerative diseases), MolMIM for generative lead molecule design, and DiffDock for molecular docking, deployed on NVIDIA NIM microservices and H100 GPU clusters. The company claims the capability to screen 5.8 million small molecules in 5-8 hours and a 10x acceleration in virtual screening versus conventional methods.
Innoplexus firmographics
Firmographics- Name
- Innoplexus
- Legal name
- Partex NV
- Website
- https://innoplexus.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Innoplexus (Partex.AI) is a Germany-based AI-native drug discovery platform combining AlphaFold2, MolMIM, and DiffDock on NVIDIA H100 infrastructure to accelerate virtual screening and incubate therapeutic assets for pharmaceutical and biotech partners.
- Ownership category
- akta.pro rank
Innoplexus industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Custom Computer Programming Services (541511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- Services-Computer Programming Services (7371), Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI) (HDAEANAI)
Keywords
Where Innoplexus is headquartered
LocationHeadquarters
- HQ city
- Eschborn
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Innoplexus business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Drug Discovery Platform Services: Provides AI-driven drug discovery solutions through its Partex.AI platform with multiple business verticals including Therapeutics, Exchange, Labs, and Real-World Data
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Innoplexus product offering
Product offeringCore offering
Innoplexus (Partex.AI) provides an AI-driven drug discovery platform that accelerates identification and optimization of therapeutic assets for the life sciences industry. Its offering is organized into four business units—Therapeutics (incubating late preclinical to early clinical drug assets in focused SPVs), Exchange (AI-enabled in- and out-licensing of deprioritized drug assets), Labs (functional assays and high-throughput experimental validation), and Real-World Data (RWD partnerships with healthcare providers)—all powered by proprietary AI models running on NVIDIA GPU infrastructure.
Product overview
Partex.AI (affiliated with Innoplexus) operates as an AI-powered therapeutic asset accelerator with four integrated business units: Therapeutics incubates drug assets, Exchange facilitates licensing transactions, Labs provides experimental validation, and Real-World Data enables evidence generation. The AI-driven drug discovery pipeline serves as the underlying technology platform powering all units, utilizing NVIDIA infrastructure for computational drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- Therapeutics: Identifying late stage preclinical - early clinical drug assets with strong scientific foundations but suboptimal development paths, Partex.AI's proprietary models optimize therapeutics towards their key value inflection.
- Exchange
- Labs
- Real-World Data
Products and services
- Therapeutics Identifies late-stage preclinical to early clinical drug assets with strong scientific foundations but suboptimal development paths, using Partex.AI's proprietary models to optimize therapeutics toward their key value inflection points. Designed for pharmaceutical and biotechnology partners seeking to advance or reposition therapeutic candidates.
- Exchange AI-driven in-licensing and out-licensing platform that enables pharma and biotech partners to unlock value from deprioritized or off-strategy drug assets through data-enabled asset evaluation and repositioning. Targets pharmaceutical and biotechnology companies seeking efficient pipeline optimization.
- Labs Next-generation functional assays and high-throughput experimental screening service that rigorously tests and confirms AI-driven predictions by integrating computational modeling with hands-on laboratory science in disease-relevant systems, forming a closed-loop validation model. For pharma and biotech partners requiring experimental confirmation of AI hypotheses.
- Real-World Data Global partnerships with healthcare providers that leverage Real-World Data for drug development and treatment optimization, enabling equitable and trustworthy data utilization to improve patient outcomes. Targets pharmaceutical and biotech organizations seeking evidence generation.
- AI-Driven Drug Discovery Pipeline High-throughput AI pipeline combining AlphaFold2 protein structure prediction, MolMIM generative lead optimization, and DiffDock molecular docking on NVIDIA H100 GPU infrastructure, capable of screening 5.8 million small molecules in 5–8 hours with 10x acceleration. Built for pharmaceutical and biotechnology organizations pursuing accelerated therapeutic candidate identification.
Quantifiable outcome
- 10x acceleration in virtual screening
- +1 more outcomes
Companies that use Innoplexus
Customer profileSegments2 records
Ideal customer profiles2 records
Innoplexus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature4 records
Innoplexus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreInnoplexus leverages NVIDIA NIM microservices and H100 GPU clusters for its AI-driven drug discovery pipeline, utilizing NVIDIA's high-performance computing infrastructure for virtual screening and molecular modeling
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Innoplexus competitors and assessment
Company assessmentDirect peers
- Schrödinger: Public computational chemistry and AI drug discovery platform offering both SaaS/pharma software and an internal drug pipeline. Directly comparable to Partex.AI in combining AI platform technology with internal therapeutic asset development for pharma/biotech customers.
- Exscientia: AI-driven drug discovery company combining generative AI design with laboratory validation to develop small molecule therapeutics, with both partnered programs and wholly-owned assets. Closely mirrors Partex.AI's combination of AI pipeline + asset incubation + pharma licensing model.
- Insilico Medicine: End-to-end AI drug discovery company operating a generative biology platform for target identification, lead generation, and clinical development, including internal pipeline assets. Directly comparable to Partex.AI's Therapeutics + Labs integrated approach.
- Recursion Pharmaceuticals: AI-driven drug discovery combining high-throughput experimental biology with machine learning to identify therapeutic candidates at scale, with multiple internal programs and big-pharma partnerships. Comparable breadth of platform + internal pipeline model.
- Atomwise: AI-driven small molecule discovery platform using convolutional neural networks for virtual screening and lead identification, partnered with pharma on multiple programs. Comparable AI-first virtual screening service offered to pharma customers.
- BenevolentAI: AI drug discovery company combining biomedical knowledge graphs with machine learning for target identification and drug repositioning, partnered with major pharma. Comparable AI-driven target identification and pharma licensing motion to Partex.AI.
Emerging players
- Iambic: AI-driven drug discovery startup focused on generative chemistry and physics-inspired models for drug design, with both partnered and internal programs. Comparable AI-first discovery approach but at earlier stage and narrower scope than Partex.AI.
- Lantern Pharma: AI-driven oncology drug development company using machine learning to identify and develop therapeutic candidates, particularly for rare cancers. Comparable AI + oncology asset incubation model but smaller scale and narrower therapeutic focus.
Broad incumbents
- Tempus AI: AI and data-driven precision medicine company leveraging large-scale real-world clinical and molecular data for drug development and patient care. Overlaps with Partex.AI's Real-World Data vertical while operating a much broader healthcare AI business.
- Owkin: AI-driven medical research and drug discovery company combining federated learning and real-world patient data with pharma partnerships across multiple therapeutic areas. Comparable AI-pharma platform model with broader healthcare data infrastructure focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Innoplexus social profiles
Digital presenceInnoplexus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Innoplexus leadership team
Management profileNumber of profiles
Profiles4 records
Innoplexus funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Innoplexus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Innoplexus
What does Innoplexus do?
Innoplexus (Partex.AI) provides an AI-driven drug discovery platform that accelerates identification and optimization of therapeutic assets for the life sciences industry. Its offering is organized into four business units—Therapeutics (incubating late preclinical to early clinical drug assets in focused SPVs), Exchange (AI-enabled in- and out-licensing of deprioritized drug assets), Labs (functional assays and high-throughput experimental validation), and Real-World Data (RWD partnerships with healthcare providers)—all powered by proprietary AI models running on NVIDIA GPU infrastructure.
Is Innoplexus a public or private company?
Innoplexus is a private company. It is classified as venture growth investor backed and is currently operating.
When was Innoplexus founded?
Innoplexus was founded in 2011. It employs 251 to 500 people.
Where is Innoplexus based?
Innoplexus is headquartered in Eschborn, Germany, in the Europe region.
How does Innoplexus make money?
One revenue line is on record: drug Discovery Platform Services.
Who are Innoplexus's main competitors?
Direct peers on record are Schrödinger, Exscientia, Insilico Medicine, Recursion Pharmaceuticals, Atomwise and BenevolentAI. Emerging players are Iambic and Lantern Pharma. Broad incumbents are Tempus AI and Owkin.
Does Innoplexus have an API?
No public API is recorded for Innoplexus.
What industry is Innoplexus in?
Innoplexus's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 541511 and its SIC code is 7371.